Gastric squamous cell carcinoma

Summary

Gastric squamous cell carcinoma (MONDO:0006230) is a cancer and 5 clinical trials. Top therapeutic interventions include oxaliplatin and pralatrexate. A subtype of gastric carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Clinical trials: 5

Clinical features

Epidemiology

Prevalence records

25 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.115	Europe	Validated
Annual incidence	<1 / 1 000 000	0.063	Austria	Validated
Annual incidence	<1 / 1 000 000	0.025	Belgium	Validated
Annual incidence	<1 / 1 000 000	0.08	Bulgaria	Validated
Annual incidence	<1 / 1 000 000	0.034	Croatia	Validated
Annual incidence	<1 / 1 000 000	0.092	Czech Republic	Validated
Annual incidence	1-9 / 1 000 000	0.176	Estonia	Validated
Annual incidence	<1 / 1 000 000	0.065	Finland	Validated
Annual incidence	<1 / 1 000 000	0.08	France	Validated
Annual incidence	<1 / 1 000 000	0.079	Germany	Validated
Annual incidence	<1 / 1 000 000	0.043	Iceland	Validated
Annual incidence	1-9 / 1 000 000	0.207	Ireland	Validated
Annual incidence	1-9 / 1 000 000	0.1	Italy	Validated
Annual incidence	1-9 / 1 000 000	0.401	Latvia	Validated
Annual incidence	1-9 / 1 000 000	0.137	Lithuania	Validated
Annual incidence	<1 / 1 000 000	0.031	Malta	Validated
Annual incidence	<1 / 1 000 000	0.046	Norway	Validated
Annual incidence	<1 / 1 000 000	0.04	Poland	Validated
Annual incidence	1-9 / 1 000 000	0.115	Portugal	Validated
Annual incidence	1-9 / 1 000 000	0.111	Slovakia	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric squamous cell carcinoma
Mondo ID	MONDO:0006230
EFO	EFO:1000278
Orphanet	418959
DOID	DOID:5516
NCIT	C5475
SNOMED CT	766980008
UMLS	C1333789
MedGen	234302
GARD	0021743
Anatomy (UBERON)	UBERON:0000945
Is cancer (heuristic)	yes

Also known as: gastric (stomach) squamous cell cancer · gastric squamous cell carcinoma · squamous cell carcinoma of stomach · squamous cell carcinoma of the stomach · stomach squamous cell carcinoma

Disease family

This is a subtype of gastric carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gastric cancer › gastric carcinoma › gastric squamous cell carcinoma

Related subtypes (11): gastric cardia carcinoma, gastric fundus carcinoma, gastric pylorus carcinoma, gastric body carcinoma, stomach carcinoma in situ, gastric adenocarcinoma, gastric small cell neuroendocrine carcinoma, Epstein-Barr virus-associated gastric carcinoma, hereditary gastric cancer, carcinoma of stomach, salivary gland type, undifferentiated carcinoma of stomach

Subtypes (1): gastric adenosquamous carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT01178944	PHASE2	COMPLETED	Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
NCT02830594	PHASE2	COMPLETED	Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
NCT07284186	PHASE1	RECRUITING	First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT06560645	PHASE1	TERMINATED	A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OXALIPLATIN	4	1
PRALATREXATE	4	1